ABUS Arbutus Biopharma Corp: institutional ownership and insider trading
193 funds reported holding $676M of Arbutus Biopharma Corp in their latest 13F filings; in Q2 2026 funds net bought $2.27M, with 33 new positions and 24 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
Famous investors holding ABUS
- Ken Griffin (Citadel Advisors): $1.94M, 0.0% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $1.83M, 0.0% of the portfolio
- Two Sigma (Two Sigma Investments): $408K, 0.0% of the portfolio
Largest institutional holders of ABUS
- MORGAN STANLEY (MS, MS-PA, MS-PE, MS-PF, MS-PI, MS-PK, MS-PL, MS-PO, MS-PP, MS-PQ) — $85.0M
- Whitefort Capital Management, LP — $75.8M
- BlackRock, Inc. (BLK) — $66.1M
- VANGUARD GROUP INC — $44.5M
- Two Seas Capital LP — $38.9M
- STATE STREET CORP (STT, STT-PG) — $37.8M
- Rubric Capital Management LP — $36.2M
- VANGUARD CAPITAL MANAGEMENT LLC — $33.7M
- BARCLAYS PLC (BCS, BCLYF) — $20.2M
- GEODE CAPITAL MANAGEMENT, LLC — $19.8M
Recent ABUS insider trades
- Feb 4, 2025: Hastings David C sold 22,183 shares ($72.8K)
- Feb 4, 2025: Sims Karen sold 19,348 shares ($63.5K)
- Feb 4, 2025: McElhaugh Michael J. sold 23,790 shares ($78.0K)
- Feb 4, 2025: Naftzger J. Christopher sold 11,333 shares ($37.2K)
5%+ owners
- Roivant Sciences Ltd.: 19.5% (Schedule 13D/A, filed Oct 5, 2026)
- Morgan Stanley: 12.2% (Schedule 13G/A, filed Oct 7, 2026)
- Two Seas Capital LP: 9.4% (Schedule 13G/A, filed May 15, 2026)
- Whitefort Capital Master Fund, LP: 8.0% (Schedule 13G, filed Sep 4, 2026)